Imatinib directly inhibits KIT tyrosine kinase activity (ATP-competitive), blocking downstream survival/proliferation signaling (e.g., PI3K/AKT, RAS/MAPK), leading to growth arrest and apoptosis of KIT-dependent tumor cells.